Direvo Industrial Biotechnology GmbH (Direvo IBT) was founded in 2008 by the shareholders of its mother company, Direvo Biotech AG, which had been acquired by Bayer Healthcare for $300 million.

Direvo Biotech AG commenced operation in 2000 as one of the world’s leading developers of directed evolution technologies. Many times, over the years, its proprietary evolution platform has demonstrated the outstanding ability to develop tailored enzymes for both health care and industrial applications.

Direvo IBT retained all rights to the directed evolution technology and intellectual property for application in non-pharmaceutical industries and became fully operational in early 2009 in its state-of-the-art laboratories in Cologne.

Since then we are deploying a decade of enzyme, microbe and process know-how to develop bio-based solutions for our partners and customers in the clean energy, clean chemistry and biomass conversion markets.